Combined capabilities provide scientists with access to new and existing immortalized cell lines for use in broad research applications and clinical markets.
ATCC, the premier global biological materials resource and standards organization, and Evercyte GmbH, a proven developer of immortalized human cells, have entered into a strategic partnership to develop and distribute immortalized cell lines that retain key performance characteristics of primary cells. Immortalized primary cell lines enable scientists to have a sufficient supply of physiologically relevant cells for extended studies in biological, medical, pharmaceutical, cosmetic, and toxicological research.
{iframe}http://www.atcc.org/~/media/PDFs/2013%20Press%20Releases/Evercyte%20press%20release.ashx{/iframe}